Literature DB >> 1512021

In vivo growth inhibitory effect of Withania somnifera (Ashwagandha) on a transplantable mouse tumor, Sarcoma 180.

P U Devi1, A C Sharada, F E Solomon, M S Kamath.   

Abstract

Withania somnifera is a medicinal plant used in the treatment of a variety of ailments in the Ayurvedic system. Alcoholic extract of the root of the plant was injected(ip) at daily doses of 200 to 1000 mg/kg body wt for 15 days starting from 24 hr after intradermal inoculation of 5 x 10(5) cells of S-180 in BALB/c mice. Solid tumor growth was monitored for 100 days. Doses of 400 mg/kg and above produced complete regression of tumor after an initial growth, the percentage of complete response (CR) increasing with increasing drug dose. A 55% CR was obtained at 1000 mg/kg drug administration, but this dose also produced some mortality among the animals. A significant increase in the volume doubling time and growth delay was seen when the drug dose was increased from 500 to 750 mg/kg body wt, but further increase in drug dose to 1000 mg/kg did not produce any significant increase in these responses. Cumulative doses of 7.5 to 10 g at daily doses of 500 or 750 mg/kg seems to produce a good response in this tumor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512021

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  21 in total

1.  Functional characterization and differential expression studies of squalene synthase from Withania somnifera.

Authors:  Neha Gupta; Poonam Sharma; R J Santosh Kumar; Rishi K Vishwakarma; B M Khan
Journal:  Mol Biol Rep       Date:  2012-06-21       Impact factor: 2.316

2.  Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.

Authors:  Silvia D Stan; Eun-Ryeong Hahm; Renaud Warin; Shivendra V Singh
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

3.  RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells.

Authors:  Su-Hyeong Kim; Eun-Ryeong Hahm; Krishna B Singh; Sruti Shiva; Jacob Stewart-Ornstein; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

4.  Influence of plant growth regulators on callus mediated regeneration and secondary metabolites synthesis in Withania somnifera (L.) Dunal.

Authors:  Nilanjan Chakraborty; Debarupa Banerjee; Moumita Ghosh; Prakash Pradhan; Namrata Shanu Gupta; Krishnendu Acharya; Maitreyi Banerjee
Journal:  Physiol Mol Biol Plants       Date:  2013-01

Review 5.  Withaferin A and its potential role in glioblastoma (GBM).

Authors:  Jasdeep Dhami; Edwin Chang; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2016-11-11       Impact factor: 4.130

6.  Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells.

Authors:  Eun-Ryeong Hahm; Joomin Lee; Yi Huang; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2011-03-22       Impact factor: 4.784

Review 7.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

Review 8.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

9.  Studies on the protective and immunomodulatory efficacy of Withania somnifera along with cisplatin against experimental visceral leishmaniasis.

Authors:  Heena Sachdeva; Rakesh Sehgal; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2013-03-22       Impact factor: 2.289

10.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.